Morgan Stanley Reaffirms Overweight Rating for Disc Medicine (NASDAQ:IRON)
Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating reiterated by Morgan Stanley in a research note issued on Friday,Benzinga reports. They presently have a $85.00 price objective on the stock. Morgan Stanley’s price objective indicates a potential upside of 52.69% from the company’s previous close. Several other research firms have also […]
Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating reiterated by Morgan Stanley in a research note issued on Friday,Benzinga reports. They presently have a $85.00 price objective on the stock. Morgan Stanley’s price objective indicates a potential upside of 52.69% from the company’s previous close. Several other research firms have also […]
